Added to YB: 2026-06-16
Pitch date: 2026-06-13
LLY [neutral]
Eli Lilly and Company
-0.41%
current return
Author Info
Kontra Invest is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Market Cap
$1.0T
Pitch Price
$1.1K
Price Target
N/A
Dividend
0.61%
EV/EBITDA
28.77
P/E
40.25
EV/Sales
14.51
Sector
Pharmaceuticals
Category
growth
Retatrutide hit 30% weight loss. The grey market already sells it. ($LLY)
LLY (overview): Retatrutide ('Triple G' GLP-1/GIP/glucagon) Phase 3 TRIUMPH-1 hit 28-30% weight loss, surgical-range, setting new bar above tirzepatide. 4mg dose (19% loss, 4% discontinuation) likely mass-market. Bull: 100M US obese, $85B 2026 guide. Risk: pricing trap vs grey-market retatrutide; Lilly Direct self-pay ($299-499) anti-counterfeit play pressures ASP. Stock ATH $1,182, ~$1.1T cap. 2027 launch key.
Read full article (5 min)